Oncology and

Modern cancer medicines that target precise mutations or boost the immune system have greatly improved the prospects of many patients. But cures remain rare, despite significant ongoing research to improve patient outcomes.

Sygnature Discovery’s scientists work across the entire span of oncology drug discovery, all the way from target identification and lead optimisation to candidate nomination and clinical positioning. The medicinal chemists, DMPK and bioscientists at Sygnature Discovery and the in vivo specialists in our translational oncology department work in integrated teams to deliver tailored services for clients.


Patients remain at the heart of every project. Cancer is no longer considered a single disease, and with that in mind our scientists work seamlessly alongside expert colleagues in inflammation, the immune system and neurological. This wider expertise helps accelerate the delivery of candidates, particularly for immuno-oncology and CNS cancer projects.

Our bioscientists are skilled in creating robust, tailored in vitro screening cascades, and state-of-the-art technologies and orthogonal biophysics platforms allow decision-enabling data to be delivered rapidly. A variety of cell culture formats enable focused experiments to be carried out to help in the lead triage process. Our in-house human Blood Donor Panel gives easy access to immune and inflammatory cells from volunteer blood.

What sets us apart is the deep experience that our scientists have gained across the breadth of oncology drug discovery and a collective knowledge base that informs decisions. Over the years, we have helped deliver five clinical candidates in the oncology arena.

Oncology Assays and Capabilities

In vitro assays to support oncology programmes include:

Cell culture formats our scientists use include:

  • 3D spheroids
  • Primary cells
  • Co-cultures

Platform techniques for immuno-oncology projects include:

In vivo models available from the translational team:

Success stories in oncology

These case studies tell the story of some of Sygnature’s successes in the oncology field:

Fibrotic Diseases

Sygnature Discovery’s integrated teams of medicinal chemists, bio scientists, DMPK and translational scientists have developed significant expertise in drug discovery in the fibrosis field, with a particular focus on kidney, liver and lung fibrosis.


Metabolic Diseases

Sygnature’s scientists have extensive experience in the field of metabolic disease, from early medicinal chemistry right through to in vivo testing. The integrated teams at Sygnature Discovery have a track record of delivering validated drug candidates to clients.


Oncology and

We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.


Anti Infectives

Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Integrated Drug Discovery teams have worked in close collaboration with many clients to design potent and efficacious compounds. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.



Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.



We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects


Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.


Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…